Source document verification in the Mucopolysaccharidosis Type I Registry

Karien Verhulst, Laura Artiles-Carloni, Michael Beck, Joe T R Clarke, Jordao Correa Neto, Gerald F. Cox, Paul M. Fernhoff, Nathalie Guffon, Yuan Kong, Ana Maria Martins, Anna Tylki-Szymanska, Chester B. Whitley, Frits A. Wijburg, Edward J. Wraith, Catherine M. Koepper

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Purpose: The Mucopolysaccharidosis Type I (MPS I) Registry is an international observational database that tracks the natural history and the outcomes of patients with MPS I. The Registry was a regulatory requirement following the approval of laronidase enzyme replacement therapy for MPS I in 2003. All data are collected voluntarily after informed consent from the patient or family. Data are checked through queries, monthly reviews, and electronic audits to identify missing, inconsistent, or invalid data. This analysis sought to determine overall data accuracy in the Registry through source document verification (SDV). Methods: Two phases of SDV were performed. In each phase, Registry data were compared against source documents at sites in Europe, Latin America, and North America. Three patients were randomly selected for SDV at each of the selected sites among all patients enrolled ≥18months and ever receiving laronidase. Key parameters central to MPS I and its treatment were examined from the baseline and the last available assessments. Results: Results indicate an overall source-to-database error rate in the MPS I Registry of 2.7% (47 discrepancies out of 1715 items; 95% confidence interval [2.2%, 3.5%]) in Phase1 and 3.7% (64 discrepancies out of 1732 items; 95% confidence interval [2.9%, 4.7%]) in Phase2. No systematic errors were found. Conclusions: The overall error rates in both phases of SDV demonstrate acceptable data accuracy in the MPS I Registry within the data fields that were assessed.

Original languageEnglish (US)
Pages (from-to)749-752
Number of pages4
JournalPharmacoepidemiology and Drug Safety
Issue number7
StatePublished - Jul 2012

Bibliographical note

Copyright 2012 Elsevier B.V., All rights reserved.


  • Enzyme replacement therapy
  • Laronidase
  • MPS I
  • Registry
  • Source document verification


Dive into the research topics of 'Source document verification in the Mucopolysaccharidosis Type I Registry'. Together they form a unique fingerprint.

Cite this